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Abstract: Renal transplant recipients (RTR) commonly suffer from vitamin B6 deficiency and its
functional consequences add to an association with poor long-term outcome. It is unknown whether
niacin status is affected in RTR and, if so, whether this affects clinical outcomes, as vitamin B6 is a
cofactor in nicotinamide biosynthesis. We compared 24-h urinary excretion of N1-methylnicotinamide
(N1-MN) as a biomarker of niacin status in RTR with that in healthy controls, in relation to dietary
intake of tryptophan and niacin as well as vitamin B6 status, and investigated whether niacin
status is associated with the risk of premature all-cause mortality in RTR. In a prospective cohort of
660 stable RTR with a median follow-up of 5.4 (4.7–6.1) years and 275 healthy kidney donors, 24-h
urinary excretion of N1-MN was measured with liquid chromatography-tandem mass spectrometry
LC-MS/MS. Dietary intake was assessed by food frequency questionnaires. Prospective associations
of N1-MN excretion with mortality were investigated by Cox regression analyses. Median N1-MN
excretion was 22.0 (15.8–31.8) µmol/day in RTR, compared to 41.1 (31.6–57.2) µmol/day in healthy
kidney donors (p < 0.001). This difference was independent of dietary intake of tryptophan (1059 ± 271
and 1089 ± 308 mg/day; p = 0.19), niacin (17.9 ± 5.2 and 19.2 ± 6.2 mg/day; p < 0.001), plasma
vitamin B6 (29.0 (17.5–49.5), and 42.0 (29.8–60.3) nmol/L; p < 0.001), respectively. N1-MN excretion
was inversely associated with the risk of all-cause mortality in RTR (HR 0.57; 95% CI 0.45–0.71;
p < 0.001), independent of potential confounders. RTR excrete less N1-MN in 24-h urine than healthy
controls, and our data suggest that this difference cannot be attributed to lower dietary intake of
tryptophan and niacin, nor vitamin B6 status. Importantly, lower 24-h urinary excretion of N1-MN is
independently associated with a higher risk of premature all-cause mortality in RTR.
Keywords: urinary excretion of N1-methylnicotinamide; kidney transplantation; mortality; niacin
status; dietary intake; tryptophan; vitamin B3
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1. Introduction
Kidney transplantation is the preferred treatment for end-stage renal disease in terms of survival,
quality of life and costs [1,2]. Advances in transplantation medicine have lifted the 1-year patient
survival higher than 90% [3]. While short-term patient outcomes are continuing to improve, the
long-term posttransplant survival has remained largely unchanged over the past few decades [4].
Compared with the general population, renal transplant recipients (RTR) are at highly increased risk of
premature mortality [5]. Improving perspectives relies on the management of modifiable factors that
impact long-term outcome in RTR, of which nutrition is increasingly acknowledged [6,7].
Recently, we found that RTR commonly suffer from vitamin B6 deficiency and its functional
consequences that add to an association with poor long-term outcomes [8]. As vitamin B6 is an essential
cofactor of key enzymes involved in de novo biosynthesis of nicotinamide from tryptophan [9], niacin
deficiency might be lurking in these patients as well. Nicotinamide, nicotinic acid, and nicotinamide
riboside are collectively referred to as niacin or vitamin B3, and are precursors of the metabolically
active NAD+. Besides dietary intake of pre-formed niacin, the so-called tryptophan-nicotinamide
pathway is critical to maintaining niacin status [10]. Ongoing NAD+ supply from its metabolic
precursors, collectively referred to as “niacin equivalents”, is required to provide reducing equivalents
for energy metabolism and substrates of NAD+ consuming enzymes [11]. NAD+ is catabolized to
N1-methylnicotinamide (N1-MN) through methylation of nicotinamide in the liver, and the 24-h
urinary excretion of N1-MN is considered the most reliable biomarker of niacin status [12–14].
It is unknown whether niacin status is affected in RTR and, if so, whether this affects clinical
outcomes. Hence, this study aims to compare 24-h urinary excretion of N1-MN in RTR with that
in healthy kidney donors, in relation to dietary intake of tryptophan and niacin as well as vitamin
B6 status, and to investigate whether niacin status is associated with the risk of premature all-cause
mortality in RTR.
2. Materials and Methods
2.1. Study Population
This prospective study was conducted in a well-characterized, single-center cohort of 707 RTR
(aged ≥18 years) with a functioning graft for at least 1 year who visited the outpatient clinic of the
University Medical Center Groningen, Groningen, the Netherlands, between 2008 and 2011 [15–17].
As a control group, 367 healthy kidney donors were included who participated in a screening program
before kidney donation. Signed informed consent was obtained from all participating subjects and
the study protocol was approved by the institutional review board (METc 2008/186) adhering to the
Declaration of Helsinki. Exclusion of subjects with missing biomaterial or niacin supplementation use
left 660 RTR and 275 kidney donors eligible for statistical analyses (Figure S1).
2.2. Data Collection
All baseline measurements were obtained during a morning visit to the outpatient clinic.
Participants were instructed to collect a 24-h urine sample on the day before their visit, and to
fast overnight for 8 to 12 h. Urine samples were collected under oil, and chlorhexidine was added as
an antiseptic agent. Fasting blood samples were drawn after completion of the urine collection. Blood
was collected in a series of evacuated tubes with different additives (Vacutainer®; BD, Franklin Lakes,
NJ, USA) for preparation of plasma and serum. Body composition and hemodynamic parameters
were measured according to a previously described, strict protocol [15]. Serum parameters, including
lipid, inflammation, and glucose homeostasis variables were measured with spectrophotometric-based
routine clinical laboratory methods (Roche Diagnostics, Rotkreuz, Switzerland). Diabetes was
diagnosed if fasting plasma glucose was ≥7.0 mmol/L or antidiabetic medication was used [15]. Plasma
vitamin B6 was determined as its principal, metabolically active form pyridoxal-5′-phosphate using a
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HPLC method (Waters Alliance, Milford, MA, USA) with fluorescence detection (JASCO, Inc., Easton,
MD, USA) [8].
Renal function was assessed by estimation of the glomerular filtration rate (eGFR) and detection
of proteinuria. The eGFR was calculated using the combined creatinine and cystatin C-based
Chronic Kidney Disease Epidemiology Collaboration equation [18], which has been shown to be the
most accurate equation in RTR [19]. Proteinuria was diagnosed if total urinary protein excretion
was ≥0.5 g/day as measured by a biuret reaction-based assay (MEGA AU510; Merck Diagnostica,
Darmstadt, Germany).
Dietary intake including tryptophan and niacin intakes was assessed with a validated
semi-quantitative food frequency questionnaire (FFQ) [20–22]. The self-administered questionnaire
was filled out at home and inquired about 177 food items during the last month, taking seasonal
variations into account. During the visit to the outpatient clinic, the FFQ was checked for completeness
by a trained researcher and inconsistent answers were verified with the participant. The FFQ was
validated for RTR as previously reported [16]. Dietary data were converted into daily nutrient intake
using the Dutch Food Composition Table of 2006 [23]. Alcohol consumption and smoking behavior
were assessed with a separate questionnaire [6]. Additional data on medical history and use of
medication and vitamin supplements were obtained from medical records [6].
2.3. Assessment of N1-MN Excretion
Measurement of N1-MN concentration was performed with a validated liquid chromatography
(Luna HILIC column; Phenomenex, Torrance, CA, USA) isotope dilution-tandem mass spectrometry
(LC-MS/MS) (Quattro Premier; Waters, Milford, MA, USA) method, as described previously [24]. The
24-h urinary excretion of N1-MN (µmol/day) was obtained after multiplying N1-MN concentration
(µmol/L) by total urine volume calculated from weight (L/day). The reference range of N1-MN excretion
in healthy individuals was previously established at 17.3–115 µmol/day [24].
2.4. Clinical Endpoints
The primary outcome of this study was all-cause mortality which was recorded until 30 September
2015 with no loss due to follow-up. RTR status was kept up-to-date through the continuous surveillance
system of the outpatient program.
2.5. Statistical Analysis
Data are presented as the mean± SD, median (IQR) and absolute number (percentage) for normally
distributed, skewed, and nominal data, respectively. Assumptions for normality were checked by
visual judgments of the corresponding frequency distribution and Q-Q plot.
Baseline characteristics of RTR and healthy kidney donors were compared by means of t,
Mann-Whitney, and Chi-Square tests. Niacin status in RTR and healthy kidney donors was compared
by linear regression analyses of 2-base log-transformed N1-MN excretion, with subsequent cumulative
adjustment for age and sex (model 1), eGFR (model 2) and intake of energy, tryptophan, and niacin
and plasma vitamin B6 (model 3).
RTR characteristics were divided into tertiles of N1-MN excretion stratified by sex (T1, T2, and T3)
and compared by means of ANOVA, Kruskal-Wallis, and Chi-Square tests.
For prospective analyses, a Cox proportional hazards regression model for all-cause mortality
outcome was fitted to N1-MN excretion as a sex-stratified tertile-based categorical variable, as well as a
continuous variable adjusted for sex (model 1). Confounding was controlled for by including potential
confounders as covariates in the regression model. Crude associations were adjusted cumulatively for
age (model 2), smoking and body surface area (model 3) and, to prevent overfitting, additionally for
intake of alcohol and energy and plasma vitamin B6 (model 4), kidney function (model 5), medication
use (model 6), and high-sensitivity C-reactive protein (hs-CRP) (model 7). Variables that could lie in
the causal pathway of N1-MN excretion and all-cause mortality were not adjusted for because this
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might obscure otherwise existing associations unintentionally. Assumptions of proportionality of
the hazard functions and the linearity of log-hazards were checked by visual judgements of Kaplan
Meier plots of the survival and log-survival function entering the sex-stratified N1-MN excretion tertile
group variable.
In secondary analyses, effect modification was assessed by including the cross product term of
each potential confounder and 2-base log-transformed N1-MN excretion in the Cox regression model
adjusted for age and sex (model 2). Subsequent stratified analyses were performed for subgroups of
significant effect modifiers on the association of N1-MN excretion with all-cause mortality.
For all statistical analyses, a two-sided p-value of less than 0.05 was considered to indicate
statistical significance and SPSS Statistics version 23.0 (IBM, Armonk, NY, USA) was used as software.
3. Results
3.1. Baseline Characteristics and Comparison of N1-MN Excretion
This study included 660 stable RTR (57% male; mean age 53.0 ± 12.7 years), at a median time of 5.6
(2.0–12.0) years after transplantation, and 275 healthy kidney donors (41% male; mean age 53.3 ± 10.7
years) (Table 1). Intake of tryptophan was similar in both groups (1059 ± 271 and 1089 ± 308 mg/day,
respectively; p = 0.19), while intake of niacin was lower in RTR than in kidney donors (17.9 ± 5.2 and
19.2 ± 6.2 mg/day, respectively; p = 0.01). Taken together, intake of niacin equivalents was lower in
RTR than in kidney donors (35.6 ± 9.2 mg/day and 37.4 ± 10.8, respectively; p = 0.03) (Figure 1). All
RTR and kidney donors complied with the recommended daily intake that is set at a minimum of
6.6 niacin equivalents per 1000 kcal (≥ 9.6 and ≥ 11.7 mg/1000 kcal, respectively) [12]. As previously
reported, RTR had significantly lower plasma vitamin B6 compared to kidney donors (29.0 (17.5–49.5)
and 42.0 (29.8–60.3) nmol/L, respectively; p < 0.001). Median N1-MN excretion was 22.0 (15.8–31.8)
µmol/day in RTR, compared to 41.1 (31.6–57.2) µmol/day in kidney donors (p < 0.001) (Figure 1).
Furthermore, urinary excretion of N1-MN was below the reference limit of 17.3 µmol/day in 202 (31%)
RTR, against 4 (2%) kidney donors. The difference in N1-MN excretion between RTR and kidney donors
was independent of age, sex, eGFR, intake of energy, tryptophan, and niacin and plasma vitamin B6
(Table 2). Cyclosporine, azathioprine, and anticonvulsants were used by, respectively, 253 (38%), 112
(17%) of 19 (3%) of RTR, and none of the controls received drugs that are known to potentially affect
niacin status.
Table 1. Baseline characteristics of stable RTR compared to that in healthy kidney donors 1.
Variable Donorsn = 275
RTR
n = 660 p-Value
2
Age, years 53.3 ± 10.7 53.0 ± 12.7 0.68
Male, n (%) 112 (41) 379 (57) 0.001
Body surface area, m2 1.9 ± 0.2 1.9 ± 0.2 0.90
Current smoker, n (%) 39 (14) 78 (12) <0.001
Alcohol intake, g/day 6.7 (1.1–16.4) 3.1 (0.1–11.9) <0.001
Energy intake, kcal/day 2295 ± 746 2182 ± 642 0.04
Niacin equivalents intake, mg/day 3 37.4 ± 10.8 35.6 ± 9.2 0.03
Tryptophan intake, mg/day 1089 ± 308 1059 ± 271 0.19
Niacin intake, mg/day 19.2 ± 6.2 17.9 ± 5.2 0.01
N1-MN excretion, µmol/day 41.4 (31.6–57.2) 22.0 (15.8–31.8) <0.001
<17.3 µmol/day, n (%) 4 (2) 202 (31) 0.03
Plasma vitamin B6 (nmol/L) 42.0 (29.8–60.3) 29.0 (17.5–49.5) <0.001
Systolic blood pressure, mmHg 125.1 ± 13.9 135.8 ± 17.3 <0.001
Diastolic blood pressure, mmHg 75.6 ± 9.1 82.5 ± 11.0 <0.001
Triglycerides, mmol/L 1.2 (0.9–1.7) 1.7 (1.2–2.3) <0.001
HbA1c, (%) 5.6 (5.4–5.8) 5.8 (5.5–6.2) <0.001
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Table 1. Cont.
Variable Donorsn = 275
RTR
n = 660 p-Value
2
eGFR, ml/min/1.73 m2 91.0 ± 14.2 53.0 ± 20.0 <0.001
Acetylsalicylic acid, n (%) 4 (2) 127 (19) <0.001
Proton pump inhibitor, n (%) 5 (2) 326 (49) <0.001
Diuretic, n (%) 9 (3) 261 (40) <0.001
1 Data are presented as mean ± SD, median (IQR) and absolute number (percentage) for normally distributed,
skewed and nominal data, respectively. 2 p-value for difference was tested by t and Mann-Whitney tests for normally
and skewed distributed continuous variables, respectively, and Chi-Square tests for nominal variables. 3 Intake of
niacin equivalents was calculated by adding up niacin and one-sixtieth of tryptophan intake. Subjects who were
using niacin supplementation were excluded. eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c;
N1-MN, N1-methylnicotinamide; RTR, renal transplant recipients.
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p-
Value Std.β 
p-
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Value 
Grouping −0.42 <0.001 −0.44 <0.001 −0.25 <0.001 −0.21 <0.001 
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Figure 1. Box plots of dietary intake of (a) tryptophan, (b) niacin and (c) niacin equivalents and (d) log2
24-h urinary excretion of N1-MN in RTR compared to that in healthy kidney donors. Boxes, bars and
whiskers represent IQRs, medians and values <1.5 × IQR, respectively, whereas outliers (1.5–3 × IQR)
are indicated by circles and extreme outliers (>3 × IQR) by asterisks. Log2 of the lower and upper
bound of the reference range of N1-MN excretion in healthy individuals (17.3–115.0) µmol/day [24] are
indicated with dotted lines (d). p-value for difference between RTR and donors was tested by t and
Mann-Whitney tests for normally and skewed distributed continuous variables, respectively. Intake of
niacin equivalents was calculated by adding up niacin and one-sixtieth of tryptophan intake. N1-MN,
N1-methylnicotinamide; RTR, renal transplant recipients.
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Table 2. Association of RTR and healthy kidney donors grouping with N1-MN excretion 1.
Variable
Model 1 2 Model 2 3 Model 3 4 Model 4 5
Std.β p-Value Std.β p-Value Std.β p-Value Std.β p-Value
Grouping −0.42 <0.001 −0.44 <0.001 −0.25 <0.001 −0.21 <0.001
Sex - - −0.15 <0.001 −0.14 <0.001 −0.10 0.002
Age, years - - −0.16 <0.001 −0.11 <0.001 −0.07 0.02
eGFR, ml/min/1.73 m2 - - - - 0.31 <0.001 0.29 <0.001
Energy intake, kcal/day - - - - - - −0.10 0.08
Tryptophan intake, mg/day - - - - - - 0.007 0.91
Niacin intake, mg/day - - - - - - 0.25 <0.001
Plasma vitamin B6, nmol/L - - - - - - 0.23 <0.001
R2 0.18 0.23 0.28 0.37
1 Linear regression analyses were performed to investigate the association of RTR and healthy kidney donors as
grouping variable with N1-MN excretion, with adjustment for potential confounders. 2 Model 1: crude model.
3 Model 2: adjusted for age and sex. 4 Model 3: adjusted as for model 2 and for eGFR. 5 Model 4: adjusted as
for model 3 and for intake of energy, tryptophan and niacin and plasma vitamin B6. eGFR, estimated glomerular
filtration rate; N1-MN, N1-methylnicotinamide; RTR, renal transplant recipients; std.β, standardized beta coefficient.
RTR characteristics across tertiles of sex-stratified N1-MN excretion (M: <19.2, 19.2–28.8,
>28.8 µmol/day; F: <16.1, 16.1–25.6, >25.6 µmol/day in T1, T2, and T3, respectively) are shown
in Table 3. Age and the presence of acetylsalicylic acid, proton pump inhibitors, diuretics and post
mortem donors were lower with increasing tertiles of N1-MN excretion, while intake of alcohol, energy,
tryptophan and niacin, plasma vitamin B6, kidney function and the presence of proliferation inhibitors
and primary glomerular disease were higher with increasing tertiles of N1-MN excretion.
Table 3. Baseline characteristics of RTR across tertiles of N1-MN excretion stratified by sex 1.
Variable
Tertiles of Sex-Stratified N1-MN Excretion
p-Value 2T1
n = 219
T2
n = 221
T3
n = 220
Males, µmol/day <19.2 19.2–28.8 >28.8
Females, µmol/day <16.1 16.1–25.6 >25.6
Male, n (%) 126 (58) 127 (58) 126 (57) -
Age, years 54.6 ± 12.7 53.7 ± 13.1 50.7 ± 12.1 0.004
BMI, kg/m2 25.8 (22.7–29.4) 26.1 (23.3–29.0) 26.0 (23.6–29.6) 0.41
Body surface area, m2 1.9 ± 0.2 1.9 ± 0.2 2.0 ± 0.2 0.13
Lifestyle
Current smoker, n (%) 21 (10) 25 (11) 32 (15) 0.26
Alcohol consumption, g/day 0.5 (0.0–7.0) 3.2 (0.1–11.3) 6.7 (0.8–20.9) <0.001
Vegetarian, n (%) 7 (3) 2 (1) 3 (1) 0.16
Dietary intake
Energy, kcal/day 2065 ± 586 2197 ± 675 2285 ± 647 0.002
Tryptophan, mg/day 1001 ± 253 1063 ± 273 1112 ± 274 <0.001
Niacin, mg/day 16.6 ± 4.9 17.6 ± 4.8 19.5 ± 5.5 <0.001
Plasma vitamin B6, nmol/L 20.3 (14.0–39.0) 29.5 (19.0–47.0) 39.0 (22.0–65.0) <0.001
Hemodynamic
Systolic blood pressure, mmHg 139 ± 18 134 ± 18 135 ± 16 0.01
Diastolic blood pressure, mmHg 83 ± 11 82 ± 12 83 ± 11 0.20
Mean arterial pressure, mmHg 109 ± 15 106 ± 15 106 ± 14 0.07
Heart rate, beats per minute 69 ± 11 68 ± 12 68 ± 12 0.52
Antihypertensive use, n (%) 199 (91) 193 (87) 189 (86) 0.26
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Table 3. Cont.
Variable
Tertiles of Sex-Stratified N1-MN Excretion
p-Value 2T1
n = 219
T2
n = 221
T3
n = 220
Lipids
Total cholesterol, mmol/L 5.1 ± 1.2 5.2 ± 1.1 5.0 ± 1.1 0.36
HDL, mmol/L 1.3 (1.0–1.6) 1.3 (1.1–1.6) 1.3 (1.1–1.7) 0.06
LDL, mmol/L 3.0 ± 0.9 3.1 ± 0.9 2.9 ± 0.9 0.31
Triglycerides, mmol/L 1.7 (1.3–2.3) 1.7 (1.3–2.3) 1.6 (1.1–2.2) 0.03
Statin, n (%) 122 (56) 115 (52) 112 (51) 0.55
Glucose homeostasis
Glucose, mmol/L 5.3 (4.8–6.0) 5.3 (4.8–5.9) 5.2 (4.7–6.2) 0.58
HbA1c, (%) 5.8 (5.5–6.3) 5.9 (5.6–6.1) 5.7 (5.4–6.1) 0.05
Diabetes, n (%) 58 (27) 44 (20) 50 (23) 0.26
Antidiabetic, n (%) 41 (19) 28 (13) 27 (12) 0.10
Other serum parameters
Hs-CRP, mg/L 1.7 (0.8–5.3) 1.6 (0.6–3.8) 1.4 (0.7–4.6) 0.42
Phosphate, mmol/L 1.0 ± 0.2 1.0 ± 0.2 0.9 ± 0.2 0.01
Immunosuppressant medication
Prednisolon dose, mg/day 10 (7.5–10) 10 (7.5–10) 10 (7.5–10) 0.18
Calcineurin inhibitor, n (%) 136 (62) 125 (57) 112 (51) 0.06
Cyclosporine, n (%) 87 (40) 82 (37) 84 (38) 0.85
Azathioprine, n (%) 35 (16) 36 (16) 41 (19) 0.72
Proliferation inhibitor, n (%) 171 (78) 186 (84) 191 (87) 0.04
Other medication
Acetylsalicylic acid, n (%) 55 (25) 47 (21) 25 (11) 0.001
Anticonvulsant, n (%) 7 (3) 5 (2) 7 (3) 0.80
Proton pump inhibitor, n (%) 127 (58) 107 (48) 92 (42) 0.003
Diuretic, n (%) 104 (48) 79 (36) 78 (36) 0.01
Kidney function
Serum creatinine, µmol/L 138 (104–189) 122 (101–153) 114 (94–140) <0.001
Cystatin C, mg/L 2.0 (1.4–2.8) 1.6 (1.3–2.1) 1.4 (1.2–1.9) <0.001
eGFR, ml/min/1.73 m2 39.0 ± 18.7 45.8 ± 16.9 52.7 ± 18.0 <0.001
Proteinuria ≥ 0.5 g/day, n (%) 55 (25) 39 (18) 38 (17) 0.07
Kidney transplantation
Time since transplantation, years 5.6 (1.7–12.9) 5.0 (1.5–11.0) 6.5 (2.9–12.3) 0.16
Donor
Age, years 46 (33–54) 47 (29–57) 43 (29–53) 0.22
Male, n (%) 104 (48) 110 (50) 112 (51) 0.60
Post mortem status, n (%) 161 (74) 143 (65) 121 (55) <0.001
Primary kidney disease
Primary glomerular disease, n (%) 48 (22) 67 (30) 71 (32) 0.04
Glomerulonephritis, n (%) 12 (6) 17 (8) 21 (10) 0.27
Tubulointerstitial disease, n (%) 27 (12) 30 (14) 20 (9) 0.32
Polycystic renal disease, n (%) 52 (24) 45 (20) 40 (18) 0.35
Dysplasia and hypoplasia, n (%) 9 (4) 10 (5) 9 (4) 0.97
Renovascular disease, n (%) 17 (8) 8 (4) 11 (5) 0.15
Diabetic nephropathy, n (%) 15 (7) 7 (3) 13 (6) 0.20
Other or unknown cause, n (%) 39 (18) 36 (16) 35 (16) 0.85
1 Data are presented as mean ± SD, median (IQR) and absolute number (percentage) for normally distributed,
skewed and nominal data, respectively. 2 p-value for difference was tested by ANOVA and Kruskal-Wallis tests for
normally and skewed distributed continuous variables, respectively, and Chi-Square tests for nominal variables.
eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein;
N1-MN, N1-methylnicotinamide; RTR, renal transplant recipients.
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3.2. N1-MN Excretion and Mortality
During a median follow-up time of 5.4 (4.7–6.1) years, 143 (22%) RTR died. The risk of all-cause
mortality increased with lower tertiles of N1-MN excretion, as depicted by Kaplan-Meier curves
(Figure 2). Cox regression analyses revealed an inverse association of N1-MN excretion with all-cause
mortality (Model 2: HR 0.57; 95% CI 0.45–0.71; p < 0.001), independent of potential confounders
(Table 4). The same held for analyses across tertiles of sex-stratified N1-MN excretion (Table 4). RTR
in the lowest and middle tertiles were at higher risk of all-cause mortality compared to those in the
highest tertile as reference (Model 2: HR 2.68; 95% CI 1.67–4.33; p < 0.001 and HR 2.04; 95% CI 1.25–3.34;
p = 0.004, respectively), independent of potential confounders (Table 4).
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Table 4. Association of N1-MN excretio it risk of all-cause mortality in RTR 1.
Model
N1-MN Excretion (log2) As
Continuous Variable n = 660
Tertiles of Sex-Stratified N1-MN Excretion 2
T1
n = 219
T2
n = 221
T3
n = 220
HR (95% CI) p-Value HR (95% CI) p-Value R (95% CI) p-Value Reference HR
1 3 0.53 (0.43–0.65) <0.001 3.28 (2.04–5.26) <0.001 2.41 (1.48–3.93) <0.001 1.00
2 4 0.57 (0.45–0.71) <0.001 2.68 (1.67–4.33) <0.001 2.04 (1.25–3.34) 0.004 1.00
3 5 0.59 (0.47–0.74) <0. 01 2.65 (1.60–4.39) <0.0 1 2.10 (1.25–3.52) .005 1.00
4 6 0.69 (0.53–0.90) 0.005 2.10 (1.17–3.78) 0.01 2.04 (1.15–3.63 0.02 1.00
5 7 0.75 (0.58–0.96) 0.02 1.86 (1.07–3.25) 0.02 1.80 (1.04–3.13) 0.04 1.00
6 8 0.65 (0.51–0.82) <0.001 2.25 (1.35– .75) 0.002 2.06 (1.23–3.46) 0.006 1.00
7 9 0.60 (0.48–0.76) <0.001 2.59 (1.54–4.35) <0.001 2.13 (1.26–3.61) 0.005 1.00
Events (n) 143 67 53 23
1 Cox regression analyses were performed to investigate the association of N1-MN excretion with risk of all-cause
mortality in RTR, with adjustment for potential confounders. 2 N -MN excretion was <19.2, 19. 2–28.8, and
>28.8 µmol/day for males, and <16.1, 16.1–25.6, and >25.6 µmol/day for females in T1, T2, and T3, respectively.
3 Model 1: not adjusted in tertiles of sex-stratified N1-MN excretion, adjusted for sex in continuous analyses.
4 Model 2: adjusted as for model 1 and for age. 5 Model 3: adjusted as for model 2 and for smoking and body surface
area. 6 Model 4: adjusted as for model 3 and for intake of alcohol and energy and plasma vitamin B6. 7 Model 5:
adjusted as for model 3 and for eGFR, proteinuria, donor status and primary glomerular disease. 8 Model 6:
adjusted as for model 3 and for use of proliferation inhibitors, acetylsalicylic acid, proton pump inhibitors and
diuretics. 9 Model 7: adjusted as for model 3 and for hs-CRP. eGFR, estimated glomerular filtration rate; hs-CRP,
high-sensitivity C-reactive protein; N1-MN, N1-methylnicotinamide; RTR, renal transplant recipients.
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Secondary analyses exposed significant effect modification of hs-CRP on the association of N1-MN
excretion with all-cause mortality (p = 0.05), independent of age and sex. The inverse association of
N1-MN excretion with all-cause mortality was stronger for individuals in the subgroup with serum
hs-CRP <2.4 mg/L (HR 0.47; 95% CI 0.35–0.64; p < 0.001), than in the subgroup with serum hs-CRP
≥2.4 mg/L (HR 0.70; 95% CI 0.50–0.96; p = 0.03) according to subsequent stratified analysis.
4. Discussion
In this large prospective cohort study, we showed that RTR excrete less N1-MN in 24-h urine than
healthy controls and our data suggest that this difference cannot be attributed to lower dietary intake
of tryptophan and niacin, nor vitamin B6 status. Furthermore, lower 24-h urinary excretion of N1-MN
as a biomarker of niacin status was independently associated with a higher risk of premature all-cause
mortality in RTR.
To the best of our knowledge, niacin status has not been studied within the context of kidney
transplantation and its concomitant long-term implications yet. In fact, prospective data on the urinary
excretion of N1-MN have been limited to one previous study in patients recovering from leukemia
treatment [25]. Studies on niacin nutrition in relation to prospective outcomes are likewise scarce,
as the prevailing intake of niacin equivalents is suggested to be not sufficiently low to compromise
survival. Presumed health benefits of niacin are pharmacological rather than physiological [26–29],
although higher survival with higher niacin intake in elderly has been reported previously [30] in
congruence with our findings.
Niacin is considered the least critical vitamin to meet the recommendations through dietary intake
in western societies [31], as niacin equivalents are found in a wide range of foods [12]. In line with this,
dietary intake of niacin equivalents was sufficient according to WHO guidelines in all RTR and healthy
kidney donors, while we found that urinary excretion of N1-MN was commonly below the established
reference bound in RTR. The observed disparity of N1-MN excretion between RTR and healthy kidney
donors could moreover not be explained by lower dietary intake of niacin equivalents in RTR in the
present study.
The fact that we found a positive association of plasma vitamin B6 concentration with N1-MN
excretion strengthens our hypothesis that inadequacies of this cofactor might affect niacin status in RTR.
Adjustment for plasma vitamin B6, however, neither did alter the discrepancy of N1-MN excretion
between RTR and healthy kidney donors. Therefore, one should consider other factors that could
interfere with N1-MN excretion as a biomarker of niacin status, and add to poor long-term outcome
in RTR.
Whereas secondary dietary inadequacies may interrupt niacin metabolism, this also holds for
certain medications including specific antituberculosis, anticonvulsant and antiproliferative drugs, as
well as cyclosporine and azathioprine [32–34], which are common immunosuppressant drugs in RTR,
although in our population those did not appear to affect N1-MN excretion.
We can furthermore speculate on the presence of enhanced consumption of tryptophan for protein
biosynthesis at the cost of niacin status in RTR. Interestingly, tryptophan is argued to be quantitatively
the most important NAD+ precursor, as it is more effective in elevating liver NAD+ and urinary
excretion of N1-MN than the salvageable precursors [35–38]. The tryptophan-nicotinamide pathway
is, however, mainly regulated by tryptophan intake rather than niacin status, since the generally
accepted conversion ratio of 60:1 falls when dietary tryptophan is limiting [39]. Indeed, tryptophan
is used primarily for protein biosynthesis and only after nitrogen balance has been achieved for the
nicotinamide pathway [40]. This allows us to speculate on protein catabolism and negative protein
balance as part of protein-energy wasting in RTR, engendered by metabolic derangement, systemic
inflammation, acidemia, and the use of immunosuppressive drugs, to induce tryptophan consumption
for protein synthesis in this population [41,42]. However, as our study was not designed to assess
protein-energy wasting, we cannot conclusively address such an effect on N1-MN excretion in RTR.
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On the contrary, the tryptophan-nicotinamide pathway is implicated in disease states in which
systemic inflammation is present, by the enhanced action of indoleamine 2,3-dioxygenase in response
to inflammatory cytokines and mediators. This upregulation of tryptophan degradation towards
nicotinamide is known to yield relativity large amounts of quinolinic acid to fuel NAD+-consuming
poly (ADP-ribose) polymerase (PARP) reaction in response to immune-related (oxidative) damage [35].
Although we observed lower serum hs-CRP levels as a low-grade inflammation biomarker with higher
tertiles of N1-MN excretion, this difference did not reach significance.
Finally, the renal clearance of N1-MN itself can also be affected by several factors and not in the
least by impaired kidney function. In fact, N1-MN is eliminated almost exclusively by the kidneys,
being partly excreted partly by glomerular filtration and partly by tubular secretion with negligible and
saturable tubular reabsorption [43]. Whereas renal clearance ofN1-MN has been investigated as a model
of renal secretory function [43] and to predict renal clearance of cationic drugs in renal insufficiency [44],
plasma concentrations are suggested to be less sensitive to kidney function because of the contribution
of aldehyde oxidase to N1-MN clearance, yielding N1-methyl-2-pyridone-5-carboxamide (2Py) [45].
Although our findings appeared independent of kidney function, future studies are warranted to rule
out enhanced oxidative metabolism, causing a shift towards urinary excretion of 2Py in this population.
Regarding potential mechanisms for the association of N1-MN excretion with mortality, NAD+
homeostasis has been linked to increased resistance against a range of pathophysiological processes that
are predominant and impact poor long-term outcome in RTR, including cardiovascular, inflammatory,
malignant and metabolic disorders [46]. The availability of NAD+ is determined by its production
from niacin equivalents, as well as its degradation in NAD+ consuming activities [47]. NAD+ levels
remain constant when used as a coenzyme, being recycled back and forth between its oxidized and
reduced forms [11], but are depleted by three distinct classes of enzymes that consume NAD+ as a
substrate: PARP, cyclic ADP ribose synthases (CD38 and CD157), and sirtuins [48]. Excessive activation
of PARP and CD38 is induced by stresses such as inflammation, oxidative stress and DNA damage that
are predominant in in RTR [48,49]. As a result, NAD+ availability might become limiting for beneficial
sirtuin activities; in particular with lower niacin status. These beneficial effects of sirtuins have been
described more specifically for renal diseases, including renoprotective effects by inhibition of renal
cell apoptosis, inflammation, and fibrosis and regulation of mitochondrial function and glucose, lipid,
and energy metabolism [50–53].
Whereas we did not find an association of N1-MN excretion with hs-CRP, this low-grade
inflammation biomarker appeared to affect the magnitude of the inverse association of N1-MN
excretion with all-cause mortality. Although we can only speculate on the underlying mechanism,
earlier mentioned inflammation-related overconsumption of NAD+ limiting its downstream beneficial
activities might at least partly explain the lower protective effect of niacin status on mortality in the
subgroup with higher serum hs-CRP levels.
The current study should be interpreted within its strengths and limitations. First, its observational
nature prohibits causal inferences, but it also did not allow us to draw conclusions on underlying
mechanisms of lower N1-MN excretion in RTR and its contribution to worse survival. Second, the
generalizability of our findings might be compromised by overrepresentation of Caucasian individuals
from a single center, despite being controlled for by the inclusion of a large, representative control
group. Third, the reliability of FFQ data is subject to sources of measurement error, including recall
and social desirability biases and limitations in food composition databases [54]. Higher similarity
in dietary sources could be achieved by including spouses as a control group. Finally, the present
study is confined to the 24-h urinary excretion of N1-MN as the recommended biomarker of niacin
nutritional status by authorities, including the WHO and the European Food Safety Authority [12–14].
Future studies are, however, encouraged to elaborate on plasma concentrations of niacin and its
metabolites, or NAD+ and the ratio of NAD+ to NADP+ in erythrocytes as additional indices of niacin
status. Although observational evidence is inherent to limitations, prospective cohort studies provide
a strong design to address nutritional status and health outcome associations over a long period of
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time. Strengths of our study include its large sample size, with a sufficient number of incident cases
and no loss to follow-up, and therefore minimizing the risk of bias in the assessment of outcome. The
extensive characterization of participants, moreover, allowed us to control for confounding and effect
modification in estimates of the effect.
5. Conclusions
In conclusion, 24-h urinary excretion of N1-MN as a biomarker of niacin status is lower in RTR
than in healthy controls, and other factors than dietary intake of niacin equivalents and vitamin B6
status appear to reinforce this discrepancy. Importantly, 24-h urinary excretion of N1-MN is inversely
associated with a higher risk of premature all-cause mortality in RTR and niacin status is therefore
revealed as a potential target for nutritional strategies to improve long-term outcome after kidney
transplantation. However, further research is warranted to unravel underlying mechanisms that
potentially interfere with N1-MN excretion in RTR, and to strengthen causal inferences for health
outcomes to support dietary recommendation.
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